Xuyang Song, Ph.D., MBA, has over 15 years of experience in global
drug development, spanning from drug discovery to drug approval
for both large and small molecules in the fields of oncology,
autoimmune diseases, and other disease areas. He has
participated in multiple INDs, BLAs, and several pivotal clinical
studies, successfully obtaining approvals from global regulatory
agencies and contributing to the successful market launch of two
innovative drugs, IMFINZI® and Imjudo®. He is particularly skilled
in AI and model-informed drug development, applying advanced AI and quantitative methods
to guide decision-making across all stages of the drug development process.
Currently, Dr. Xuyang Song serves as the Global Head of Clinical Pharmacology and Drug
Metabolism and Pharmacokinetics (DMPK) at Adlai Nortye Ltd. (NSDAQ: ANL), where he
oversees the clinical pharmacology and DMPK work across all stages of the company’s pipeline
and leading cross-functional teams to drive the product pipeline forward. He previously held
the position of Director of Clinical Pharmacology and Quantitative Pharmacology at
AstraZeneca, leading a group of experienced clinical pharmacology scientists and
pharmacometricians supporting non-clinical through to late-stage/life cycle management
across multiple product pipelines. Prior to joining AstraZeneca, he worked as a research fellow
at the US Food and Drug Administration (FDA).
Dr. Song has published over 40 papers and abstracts in renowned international journals and
conferences and his research has been cited more than 700 times. Furthermore, he is actively
involved in industry organizations and academic exchanges. He currently serves as the
Secretary-General of the Executive Team of the Chinese Biopharmaceutical Association (CBA),
Chair of the Early Development & Drug Safety Community at the American Society for Clinical
Pharmacology and Therapeutics (ASCPT), and a committee member of the International
Innovative Drug Regulatory Committee of the China Pharmaceutical Innovation and Research
Development Association (PhIRDA) and an invited lecturer for Chinese Course on Drug
Development and Regulatory Sciences (CCDRS) at Peking University Clinical Research Institute.
Dr. Xuyang Song completed his undergraduate education at Shenyang Pharmaceutical
University. He subsequently received his Ph.D. in Pharmaceutical Science, a Master’s degree in
Biostatistics from the University of Florida, and an MBA from the University of Cambridge.
